$SJMNeutralMed

J.M. Smucker Q4 Earnings Call Highlights

J.M. Smucker said it expects profit improvement in coffee as the commodity environment moderates, while it is cautious about forecasting volume response to lower prices because consumers remain guarded. For fiscal 2027, it expects net sales roughly flat in Q1, with coffee deflation impacting more in Q2+. Uncrustables hit $1B sales; Smucker targets mid-single-digit growth in fiscal 2027. It generated $1.2B free cash flow in 2026, repaying $700M+ debt, and targets at least $1B FCF in 2027 while as

7/10
5/10
Med
Neutral
Ahead of next earnings/quarter modeling for Q1 flat sales and Q2+ coffee deflation.
Neutral-to-slightly positive on margin trajectory, offset by cautious volume assumptions and tariff refund uncertainty.

Guidance and margin/tariff assumptions shift near- to mid-term earnings expectations, with coffee deflation timing and Uncrustables growth trajectory as key drivers.

Smucker guided FY27 coffee margin improvement into the high-20% range and assumed a 10% tariff level, with volume response to lower prices forecasted cautiously.

Moderate volatility risk around earnings expectations as traders reprice coffee margin timing (Q2+) and tariff/refund uncertainty.

Background

The piece summarizes management commentary from Smucker’s Q4 earnings call, focusing on coffee economics, Uncrustables growth, and segment profitability drivers (spreads/pet/sweet baked snacks).

Why it matters

Traders can update models for FY27: Q1 net sales roughly flat, green coffee deflation impacts more in Q2+, Uncrustables mid-single-digit growth in FY27, marketing spend ~5.7% of net sales, and a 10% tariff assumption with uncertain refund timing.

Market relevance

Management provided concrete outlook parameters (margin range timing, volume caution, Uncrustables growth rate, tariff level, and leverage path) that can drive earnings estimate revisions.

Market effects

Signals how consumer-staples peers may manage commodity pass-through (coffee) and promotional discipline when consumers stay cautious.

Limited direct regional impact; mostly US retail/away-from-home channel mix commentary.

Tariff assumption and coffee commodity deflation timing can influence broader global input-cost narratives for packaged foods.

Alternative perspectives

High-20% retail coffee margin improvement is framed as a second-through-fourth-quarter event, so near-term upside may be muted if volume elasticity disappoints.

Tariff refunds are pursued but excluded from guidance; if refunds are delayed or smaller than hoped, leverage/cash deployment expectations could face incremental pressure.

Key entities

  • J. M. Smucker

    Guided FY27 coffee margin improvement timing, Uncrustables growth outlook, marketing spend, tariff assumptions, and debt reduction/leverage target.

Related articles

$SJMMedAI 9/10

Uncrustables tops $1 billion as JM Smucker posts strong Q4

JM Smucker said its Uncrustables brand surpassed $1 billion in annual sales in Q4, adding 3 million new households over the past year. The company reported Q4 earnings of $2.77 per share on $2.27 billion revenue, beating estimates of $2.65 on $2.27 billion, and shares rose over 10% after hours to $112.98. Smucker cited growth in Café Bustelo and pet brands.

$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.

$SJMMedAI 8/10

Why J.M. Smucker Stock Jumped Today

J.M. Smucker shares rose Tuesday after the company reported fiscal 2026 Q4 results that beat Wall Street. Net sales grew 6% to $2.3B, helped by price increases offsetting volume declines. Adjusted EPS rose 20% to $2.77 vs. $2.64 expected; adjusted operating income rose 14% to $59.7M. Free cash flow increased 42% to $1.2B.

$MUMed

More swings for AI stocks drag Wall Street back on the roller coaster

Wall Street swung as AI-related chip and memory stocks reversed after early gains. The S&P 500 fell 0.3% (7,386.65), the Nasdaq dropped 1% (25,678.82), and the Dow rose 0.2% (50,872.11). Micron slid 1.4% after a 10% drop; it had surged 9.9% Monday. Oil eased (Brent -3% to $91.45) but AI weakness outweighed. GSK agreed to buy Nuvalent for $10.6B, sending Nuvalent up 39.3%.

$COHRMed

Benzinga

U.S. stocks fell Tuesday as rotation out of chip and AI leaders resumed: Nasdaq 100 -3.3% to ~28,437, S&P 500 -1.6% to ~7,228, Dow -0.5% to ~50,535. Oil dropped ~6% and markets priced ~50% odds of a Fed hike by October ahead of Wednesday’s CPI. Tech led declines (XLK -5.1%); SMH fell as COHR -15.2%, MRVL -12.1%, LITE -11.8%.